EP
DGX icon

Essential Partners’s Quest Diagnostics DGX Stock Holding History

Essential Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48K Hold
7
– – ﹤0.01% 2089
2026
Q1 		$1.37K Buy
7
+3
+75% +$583 ﹤0.01% 2135
2025
Q4 		$694 Hold
4
– – ﹤0.01% 2146
2025
Q3 		$762 Hold
4
– – ﹤0.01% 2098
2025
Q2 		$719 Buy
+4
New +$695 ﹤0.01% 1592

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Essential Partners's DGX Position: Q2 2026 in Review

Essential Partners held its Quest Diagnostics (DGX) position steady in Q2 2026 at 7 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Essential Partners first reported a position in DGX in Q2 2025 and has held it in 5 quarters since. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Essential Partners held 7 shares of Quest Diagnostics worth $1.48K as of Q2 2026.
  • Essential Partners left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2089 holding.
  • Essential Partners first reported a position in Quest Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.